Overview of oritavancin

European Infectious Disease

Volumn 5, Issue 2, 2011, Pages 098-101

  Billstein, Stephan ^a   Eagle, Gina ^a  

^a MEDICINES COMPANY   (United States)

Author keywords

Antibacterial skin and skin structure infections; Antibiotics; Gram positive bacteria; Lipoglycopeptide; Oritavancin; Staphylococcus aureus

Indexed keywords

EID: 84857549393     PISSN: 17551137     EISSN: 17551145     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Allen NE, From vancomycin to oritavancin: the discovery and development of a novel lipoglycopeptide antibiotic, Anti-infect Agents Med Chem, 2010;9:23-47.
2. Belley A, McKay GA, Arhin FF, et al., Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing, Antimicrob Agents Chemother, 2010;54:5369-71.
3. Kim SJ, Cegelski L, Stueber D, et al., Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus, J Mol Biol, 2008;377:281-93.
4. Patti GJ, Kim SJ, Yu TY, et al., Vancomycin and oritavancin have different modes of action in Enterococcus faecium, J Mol Biol, 2009;392:1178-91.
5. Rubino CM, Van Wart SA, Bhavnani SM, et al., Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia, Antimicrob Agents Chemother, 2009;53:4422-8.
6. Greenblatt DJ, Zhao Y, Duan SX, et al., Effect of oritavancin on human cytochromes P450 in vitro [Poster A1-1284], Presented at: the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, 12-15 September 2009.
7. Belley A, Neesham-Grenon E, McKay G, et al., Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro, Antimicrob Agents Chemother, 2009;53:918-25.
8. McKay GA, Beaulieu S, Arhin FF, et al., Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium, J Antimicrob Chemother, 2009;63:1191-9.
9. McKay GA, Beaulieu S, Parr TR, Jr., Moeck G, In vitro post antibiotic effect studies of oritavancin against S. aureus and enterococci [Poster A-50], 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, Illinois, 17-20 September 2007.
10. Lehoux D, Arhin FF, Fadhil I, et al., Oritavancin demonstrates rapid and sustained bactericidal activity in the rat granuloma pouch model of Staphyloccocus aureus infection [Poster B-0404], 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, 27-30 September 2006.
11. Ambrose PG, Mouton JW, Khalmeter G, et al., Applying pharmacodynamics for susceptibility breakpoint selection and susceptibility testing. In: Nightingale CH, Ambrose PG, Drusano GL, Murakawa T (eds), Antimicrobial pharmacodynamics in theory and clinical practice, 2nd edition, New York: Informa Healthcare, 2007;21-44.
12. Craig WA, Pharmacodynamics of antimicrobials: General concepts and applications. In: Nightingale CH, Ambrose PG, Drusano GL, Murakawa T (eds), Antimicrobial pharmacodynamics in theory and clinical practice, 2nd edition, New York: Informa Healthcare USA, Inc, 2007;1-19.
13. Van Bambeke F, Carryn S, Seral C, et al., Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages, Antimicrob Agents Chemother, 2004;48:2853-60.
14. Rodvold KA, Gotfried MH, Loutit JS, Porter SB, Plasma and intrapulmonary concentrations of oritavancin and vancomycin in normal healthy adults [Abstract O254], Presented at: 14th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 2004.
15. Rubino CM, Bhavnani SM, Forrest A, et al., Use of pharmacokinetic-pharmacodynamic principles for decision support for short-course oritavancin dosing regimens for complicated skin and skin structure infections [Abstract O152], Presented at: 18th European Congress of Clinical Microbiolgoy and Infectious Diseases [ECCMID], 19-22 April 2008.
16. Bhavnani SM, Lehoux D, Rubino CM, et al., Use of pharmacokinetics-pharmacodynamics to support oritavancin dose selection for patients with complicated skin and skin-structure infection: clinical confirmation of proof of concept [Poster A1-1288], Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, 12-15 September 2009.
17. Boylan CJ, Campanale K, Iversen PW, et al,. Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection, Antimicrob Agents Chemother, 2003;47:1700-6.
18. Lehoux D, Laquerre K, Ostiguy V, et al., Comparative efficacy of oritavancin against methicillin-sensitive and -resistant Staphylococcus aureus strains in a neutropenic mouse thigh-infection model [Poster B-1324], Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, 12-15 September 2009.
19. Okusanya OO, Lehoux D, Van Wart SA, et al., Pharmacokinetics (PK) and pharmacokineticspharmacodynamics (PK-PD) of oritavancin against Streptococcus pyogenes using data from a neutropenic murine thigh-infection model [Poster A1-1286], Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, 12-15 September 2009.
20. Okusanya OO, Lehoux D, Van Wart SA, et al., Pharmacokinetics (PK) and pharmacokineticspharmacodynamics (PK-PD) of oritavancin against Staphylococcus aureus using data from a neutropenic murine thigh-infection model [Poster A1-1287], Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, 12-15 September 2009.
21. Dunbar LM, Milata J, McClure T, Wasilewski MM, the SIMPLIFI Study Team, 2011. Comparison of the Efficacy and Safety of Oritavancin Front-Loaded Dosing Regimens to Daily Dosing: an Analysis of the SIMPLIFI Trial, Antimicrob Agents Chemother, 55(7):3476-84.
22. Lehoux D, McKay GA, Fadhil I, et al., Efficacy of oritavancin in a mouse model of Streptococcus pneumoniae pneumonia [Poster P-1781], Presented at: 25th International Congress of Chemotherapy and the 17th European Congress of Clinical Microbiology and Infectious Diseases, 31 March - 3 April 2007.
23. Craig WA, Andes DR, Activity of oritavancin (O) versus vancomycin (V) in the neutropenic murine thigh- and lung-infection models [Abstract A-1863], Presented at:44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, 30 October - 2 November 2004.
24. Lemaire S, de Galard P, Buyck J, et al., Influence of oritavancin (ORI) on phagocytosis, generation of reactive oxygen species (ROS) and killing of intracellular S. aureus in murine and human macrophages (MP) and comparison with azithromycin (AZI) and vancomycin (VAN) [Poster A1-1360], Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Boston, 12-15 September 2010.